Articles by Melissa Badamo
In a phase 3 study, patients who received recombinant ADAMTS13 did not experience acute TTP events during prophylaxis.
Iron deficiency anemia was associated with 39% increased odds of stroke, independent of the risk factors for stroke.
While cytoreductive drugs did not reduce thrombosis risk, interferon significantly improved myelofibrosis-free survival.
Fidanacogene elaparvovec gene therapy is a safe and effective treatment for patients with hemophilia B, research shows.
Compared with placebo, crizanlizumab has superior safety and comparable efficacy in patients with sickle cell disease.
Mice treated with the novel approach had a “significantly lower tumor burden” compared with mice that received controls.
The Foundation for Sickle Cell Disease Research will evaluate VAS-101 in a phase 1 clinical study.
The FDA granted orphan drug designation to rilzabrutinib for warm autoimmune hemolytic anemia and IgG4-related disease.
Bexobrutideg, an orally bioavailable, brain-penetrant BTK degrader, is being evaluated in a phase 1a/b study.
As the most common bleeding disorder, von Willebrand disease is found in up to 1% of the United States population.
PGK1 antibody levels in patients with recovered immuno-related pancytopenia were negatively correlated with platelet levels.
Imetelstat is indicated for patients with lower-risk MDS who had an unsatisfactory response to or are ineligible to ESAs.
CTD402 will enter a single-arm, open-label, phase 1b/2 trial aimed to optimize dosing and accelerate clinical development.
Thomas Martin, MD, presented data on CAR-T, bispecifics, and BCMAs in MM the National General Medical Oncology Summit.
Detectable MRD before HSCT is associated with worse survival in patients with MDS/MPN compared with undetectable MRD.
A phase 1 clinical trial is planned to test the safety and tolerability of AUTX-703 in patients with AML.
Adding ruxolitinib before, during, and after HSCT reduced the incidence of GVHD among patients with myelofibrosis.
Amneal has received FDA Approval for lenalidomide capsules in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strength.
The phase III MIRACLE trial is evaluating annamycin combined with cytarabine for relapsed or refractory AML.
Reni-cel led to hemoglobin normalization and increased fetal hemoglobin in patients with sickle cell disease.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.